E L Renner
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
Helbling B, Mullhaupt B, Renner E, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka J, Dufour J, Malinverni R, Gonvers J, Overbeck K, Swiss Hepatitis C Cohort Study. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57:1597-603.
01.11.2008Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
01.11.2008Gut 2008; 57:1597-603
Helbling B, Mullhaupt B, Renner E L, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka Jan, Dufour J-F, Malinverni R, Gonvers J-J, Overbeck K, Swiss Hepatitis C Cohort Study
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Meyer-Wyss B, Renner E, Arn M, Meyenberger C, Borovicka J, Rossi L, Criblez D, Oneta C, Gonvers J, Rammert C, Mullhaupt B, Helbling B, Egger H, Rich P, Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Journal of viral hepatitis 2006; 13:457-65.
01.07.2006Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
01.07.2006Journal of viral hepatitis 2006; 13:457-65
Meyer-Wyss B, Renner E L, Arn M, Meyenberger Christa, Borovicka Jan, Rossi L, Criblez D, Oneta C, Gonvers J-J, Rammert C, Mullhaupt B, Helbling B, Egger Hp, Rich P, Swiss Association for the Study of the Liver (SASL)
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-9.
01.02.2005Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
01.02.2005Infection 2005; 33:25-9
Huber M, Weber R, Oppliger R, Vernazza Pietro, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E L